910746 125 x 125

An Update on Emerging S1P Therapeutics for the Management of Patients With Relapsing Multiple Sclerosis

Program Overview

This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with multiple sclerosis

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Analyze the most recent clinical trial data of S1P therapeutics for the management of patients with relapsing multiple sclerosis presented at the joint ECTRIMS-ACTRIMS Meeting.
  2. Apply data-driven treatment strategies to reduce relapse rates and improve outcomes for patients with relapsing multiple sclerosis


berger headshotJoseph R. Berger, MD (Chair)
Professor of Neurology and MS Division Co-Chief
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Dhib_Jalbut_HeadshotSuhayl Dhib-Jalbut, MD
Chairman, Department of Neurology
Professor of Neurology
Rutgers University
New Brunswick, New Jersey



Lublin_HeadshotFred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York